Maxim raised the firm’s price target on Palisade Bio (PALI) to $8 from $2 and keeps a Buy rating on the shares, citing lower risk as the firm contends that the company’s recent financing supports trials for ‘2108 and potential approval.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI: